Cell Therapeutics (NASDAQ: [[ticker:CTIC]]) and OncoGenex Pharmaceuticals (NASDAQ: [[ticker:OGXI]]), a pair of Seattle-area cancer drug developers, were added to several stock indexes compiled by Russell Investments. Both companies joined the Russell 3000 Index, which measures the performance of the 3,000 largest U.S. public companies. The Russell indexes are widely used for index funds, and as benchmarks for actively managed funds.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
